SLC39A13
protein-codingsolute carrier family 39 member 13, the group of Solute carrier family 39
Gene summary
This gene encodes a member of the LIV-1 subfamily of the ZIP transporter family. The encoded transmembrane protein functions as a zinc transporter. Mutations in this gene have been associated with the spondylocheiro dysplastic form of Ehlers-Danlos syndrome. Alternate transcript variants have been found for this gene. [provided by RefSeq, Jan 2016]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~9.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: ClinGen
The SLC39A13 gene encodes the zinc transporter 13 (ZIP13), which facilitates the transport of zinc from the Golgi apparatus to the cytosol, thereby regulating cellular zinc homeostasis. The gene was first linked to rare early-onset autosomal recessive spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS) in 2008 by two separate groups (Giunta et al., PMID: 18513683 and Fukada et al., PMID: 18985159). In addition to common EDS symptoms such as thin, soft, velvety skin and hypermobile joints, affected individuals exhibit short stature, platyspondyly, tapering fingers, clubfoot, osteopenia, and abnormal radiological findings, including irregular vertebral endplates, flattened epiphyses, enlarged metaphysis, and short, broad femoral necks. Common craniofacial dysmorphic features are protruding eyes, blue sclera, and downslanting palpebral fissures. Other phenotypes are delayed eruption of permanent teeth or oligodontia, wrinkled palm skin, and thenar atrophy. Some patients were also reported muscle weakness, gait disturbances, and corneal abnormalities, with variability between and within families. Six unique homozygous variants, including three missense, one nonsense, one recurrent small deletion, and one splicing variant, have been identified in fourteen patients from eight families across five publications (PMIDs: 18513683, 18985159, 29593477, 32295219, 36727144). The case-level data from these eight probands provide 7.7 points for genetic evidence. The pathogenic mechanism is loss-of-function, supported by experimental evidence. Phenotypes observed in null knockout (KO) mouse model align with symptoms in affected individuals (PMID: 18985159). Studies on osteoblasts, odontoblasts, and dermal fibroblasts from wildtype and KO mice indicate that ZIP13 is crucial for zinc homeostasis and connective tissue development via the BMP/TGF-beta/SMAD signaling pathway (PMID: 18985159). The amount of endogenous ZIP13 protein in patient dermal fibroblasts was significantly reduced compared to cells derived from a heterozygous parent, and zinc failed to be transported into the cytosolic region (PMID: 23213233). In vitro overexpression of the p.Gly74Asp or p.Phe162_Ala164del variants in 239T or Hela cells results in unstable ZIP13 proteins undergoing VCP-dependent degradation (PMID: 25007800). Additionally, ZIP13 transcript is upregulated by myogenic stimulation in C2C12 mouse myoblasts and human dermal fibroblasts, along with the upregulation of myogenic regulatory factors MyoD and Myogenin. Knockdown of ZIP13 expression impairs myogenic differentiation, as evidenced by undifferentiated cell morphology and decreased MYH expression. In patient-derived stem cells with the p.Gly74Asp variant, MyoD, Myogenin, and MYH mRNA and protein levels are reduced compared to healthy controls. Correcting the p.Gly74Asp variant from homozygous to heterozygous state in patient stem cells using gene editing rescues Myogenin mRNA and protein expression after eight days, suggesting ZIP13's role in myogenic differentiation (PMID: 38609428). In summary, SLC39A13 is definitively associated with autosomal recessive SCD-EDS, as demonstrated in both clinical diagnostic and research settings, and has been upheld over time. This classification was approved by the ClinGen IEM GCEP on October 25th, 2024. (SOP Version 11).
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0012873
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Dermatologic; Musculoskeletal
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SLC39A13 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001128225.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 117 | 121 | |||
| missense | 2 | 127 | 17 | 1 | 147 | |
| nonsense | 2 | 2 | 4 | |||
| start loss | 0 | |||||
| frameshift | 2 | 2 | ||||
| splice donor/acceptor (+/-2bp) | 2 | 2 | ||||
| Total | 0 | 4 | 137 | 134 | 1 | 276 |
Highest pathogenic variant AF is 0.000009307128
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001121697.2 | 9 | MANE Select | |
| Ensembl | ENSP00000354689.4 | 9 | MANE Select | |
| RefSeq | NP_001317174.2 | 8 | Standard | |
| RefSeq | NP_001428200.1 | 9 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Nuclear Receptors Meta-Pathway
- NRF2 pathway
- Zinc homeostasis
Biological Process
- cellular zinc ion homeostasis
- response to zinc ion
- connective tissue development
- zinc ion transmembrane transport
Molecular Function
- zinc ion transmembrane transporter activity
- protein binding
- protein homodimerization activity
Cellular Component
- endoplasmic reticulum
- Golgi apparatus
- integral component of membrane
- integral component of Golgi membrane
- perinuclear region of cytoplasm
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000362021
- Coding exons
- 9
- Length
- 9365
- Individuals with no LoFs
- 125707
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 29
- Defined
- 125736
- p
- 0.000115
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.26 | 170 | 223 | 0.763 | 0.0000146 | 2347 |
| Missense (PolyPhen) | 48 | 74.657 | 0.64294 | 851 | ||
| Synonymous | -0.275 | 108 | 104 | 1.03 | 0.00000768 | 819 |
| Loss of Function | 2.16 | 7 | 16.4 | 0.426 | 8.04e-7 | 181 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.00014 | 0.00014 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0.00017 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Acts as a zinc-influx transporter. {ECO:0000269|PubMed:21917916}.;
- Disease
- DISEASE: Ehlers-Danlos syndrome, spondylodysplastic type, 3 (EDSSPD3) [MIM:612350]: A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSSPD3 is an autosomal recessive form characterized by a generalized skeletal dysplasia involving mainly the spine and striking clinical abnormalities of the hands, in addition to classic features of Ehlers-Danlos syndrome. Clinical features include postnatal growth retardation, moderate short stature, protuberant eyes with bluish sclerae, hands with finely wrinkled palms, atrophy of the thenar muscles, and tapering fingers. Radiologic features include mild to moderate platyspondyly, mild to moderate osteopenia of the spine, small ileum, flat proximal femoral epiphyses, short, wide femoral necks, and broad metaphyses (elbows, knees, wrists, and interphalangeal joints). {ECO:0000269|PubMed:18513683}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.124
Intolerance Scores
- LoFtool
- 0.656
- RVIS EVS
- 0.98
- RVIS percentile EVS
- 90.38
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.485
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |